Suresh S. Ramalingam, MD, FACP, FASCO

home / authors / suresh-s-ramalingam-md-facp-fasco

Articles

Suresh S. Ramalingam, MD, FACP, FASCO

Dr Ramalingam on Updates in Lung Cancer Following the 2024 ASCO Annual Meeting

Suresh S. Ramalingam, MD, FACP, FASCO;Chandler Park, MD, MSc, FACP
June 27th 2024

Suresh S. Ramalingam, MD, FACP, FASCO, and Chandler H. Park, MD, FACP, discuss updates in non–small cell lung cancer at the 2024 ASCO Annual Meeting.

Read More

Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study

Osimertinib (osi) After Definitive Chemoradiotherapy (CRT) in Patients (pts) With Unresectable Stage (stg) III Epidermal Growth Factor Receptor-Mutated (EGFRm) NSCLC: Primary Results of the Phase 3 LAURA Study

Suresh S. Ramalingam, MD, FACP, FASCO
June 24th 2024

The LAURA study (NCT03521154) evaluates the efficacy and safety of Osimertinib as a maintenance therapy following chemoradiotherapy in patients with unresectable stage III EGFR-mutated non-small cell lung cancer.

Read More

Latest Updated Articles

Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Published: June 26th 2024 | Updated: July 1st 2024
The Role of Immunotherapy in the Treatment of First-Line ES-SCLC
Simron Singh, MD, MPH
Published: June 26th 2024 | Updated: July 1st 2024
Lutetium Lu 177 Dotatate Maintains PFS, ORR Benefits Across Subgroups in SSTR+ GEP-NETs
Kevin Kalinsky, MD, MS, professor, medical oncology division director, Department of Hematology and Medical Oncology, Emory University School of Medicine; director, Glenn Family Breast Center, Emory Winship Cancer Institute; member, Discovery and Developmental Therapeutics Research Program, Winship Cancer Institute of Emory University
Published: June 29th 2024 | Updated: July 1st 2024
postMONARCH Meets Primary End Point of Improvement of PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression
Dr Maximiliano Gelli, Gustave Roussy
Published: June 28th 2024 | Updated: July 1st 2024
TRANSMET Regimen Proves Safe, Feasible for Definitively Unresectable CRC Liver Metastasis
Gastric cancer | Image Credit: © Rasi - stock.adobe.com
Published: June 28th 2024 | Updated: July 1st 2024
Switch Ramucirumab/Paclitaxel Maintenance Yields Favorable Outcomes in HER2– Gastric Cancer